Posted on May 18, 2022 in News
Written by Jeff Patton, MD. See original article HERE. Jeff Patton, MD, CEO and board member at OneOncology, dived into the controversial role that pharmacy benefit managers (PBMs) play in formulary decision marking and how PBMs impact biosimilar utilization. In August 2019, OneOncology became one of the first to make available to practices biosimilars to […]
Read MorePosted on May 13, 2022 in News
Read original article HERE. The advent of PD-1 and PD-L1 checkpoint inhibitors has changed the treatment landscape of advanced non–small cell lung cancer (NSCLC), but only approximately 20% of patients treated with immunotherapy will be alive at 5 years. According to Melissa L. Johnson, MD, Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee […]
Read MorePosted on April 14, 2022 in News
Read original article HERE. Across OneOncology, says Edward Arrowsmith MD, MPH, clinical pathways offer a vehicle for physicians to agree on best practices and to implement them across the network. Early this year, Arrowsmith became medical director for Clinical Pathways, OneOncology. The role of clinical pathways is evolving, said Edward Arrowsmith, MD, MPH, who in […]
Read MorePosted on April 11, 2022 in News
Watch the video HERE. Stephen Schleicher, MD, MBA, chief medical officer of Tennessee Oncology, talks about lessons learned from the Oncology Care Model (OCM) and Medicare that are being used to innovate toward value-based care. As the Oncology Care Model (OCM) ends and we wait for the next model, there is a lot of innovation […]
Read MorePosted on April 7, 2022 in News
Basics of recognition, diagnosis, and treatment by Charles Bankhead, Senior Editor, MedPage Today Reviewed By Meredith McKean, MD, MPH, clinical investigator, Melanoma and Skin Cancer Research Program, Sarah Cannon Research Institute, Tennessee Oncology, Nashville Last Updated April 6, 2022 – Read original article HERE. Melanoma is a rare form of skin cancer that accounts for […]
Read More